Boehringer Ingelheim

Boehringer Ingelheim selects ChemAxon’s chemistry software

Friday, February 15, 2013 12:11 PM

Boehringer Ingelheim has chosen ChemAxon, a provider of chemistry software solutions and consulting services for life science research, as its provider for a chemistry software platform for multiple applications across R&D, supporting in-house activities and work with external collaboration partners.

More... »

Lilly reassumes sole worldwide rights for novel basal insulin analog

Monday, January 7, 2013 10:55 AM

Global pharmaceutical company Eli Lilly and Boehringer Ingelheim, a Germany-based pharmaceutical company, will adjust the scope of their diabetes alliance with respect to LY2605541, Lilly's investigational novel basal insulin analog, with Lilly reassuming sole worldwide development and commercialization rights to LY2605541.

More... »

Boehringer Ingelheim launches Hep C online resource

Tuesday, November 13, 2012 01:39 PM

Boehringer Ingelheim has launched HepCRedefined.com, an online portal to help improve the lives of those living with the hepatitis C virus (HCV) through education, information and understanding. The portal aims to redefine the HCV journey by providing downloadable and shareable resources to healthcare providers, advocates, caregivers and patients.

More... »

Ensemble, Boehringer Ingelheim collaborate on macrocycle drug candidates

Friday, November 2, 2012 10:56 AM

Ensemble Therapeutics of Cambridge, Mass., has initiated a research collaboration with Germany-based Boehringer Ingelheim to discover drug candidates of a novel class of small molecule drugs, called macrocycles, against several high-value pharmaceutical targets specified by Boehringer Ingelheim.

More... »

PFF calls for letters of intent for 2013 Young Investigator and Established Investigator awards

Wednesday, October 24, 2012 10:11 AM

The Pulmonary Fibrosis Foundation (PFF) is accepting letters of intent for its 2013 PFF Research Fund grants.  Letters of intent will be accepted until Monday, November 26.  

More... »

The CenterWatch Monthly, October 2012

Monday, October 1, 2012 01:22 PM

CRCs workload up: relative pay declining

More... »

10 pharmas form nonprofit TransCelerate to accelerate R&D of new medicines

Wednesday, September 19, 2012 02:46 PM

Ten biopharmaceutical companies have formed a non-profit organization, TransCelerate BioPharma, to accelerate the development of new medicines. Participants include Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech and Sanofi.

More... »

Boehringer Ingelheim acquires Funxional's FX125L and somatotaxin portfolio

Monday, July 23, 2012 03:49 PM

Boehringer Ingelheim has agreed to acquire global rights to Funxional Therapeutics’ FX125L compound and somatotaxin program.

More... »

Icon makes senior appointments

Monday, May 21, 2012 11:52 AM

Icon, a global provider of outsourced development services, has appointed Dr. Susan Anton as director of epidemiology and risk management practice, Icon late phase & outcomes research, and Dr. Pui Leung as senior clinical research physician, Icon Development Solutions.

More... »

Daiichi forms diabetes alliance with NGM Biopharma

Friday, March 30, 2012 03:07 PM

Tokyo-based Daiichi Sankyo has formed a partnership with San Francisco-based NGM Biopharmaceuticals to research and develop new treatments for diabetes.

More... »